Yoshito Kishi

USPTO Granted Patents = 19 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 271(Granted Patents)

Location History:

Belmont, MA (US) (1994 - 1995)
Cambridge, MA (US) (1978 - 2023)

Company Filing History:

Eisai R&d Management Co., Ltd.

patents

1 out of 940

Fujisawa Pharmaceutical Company, Ltd.

patents

where one patent can have more than one assignee

Years Active: 1978-2025

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421248 - Macrocyclic compound and uses thereof (2025-09-23),

2. 11814398 - Macrocyclic compounds and uses thereof (2023-11-14),

3. 11725015 - Macrocyclic compound and uses thereof (2023-08-15),

4. 11548898 - Synthesis of halichondrins (2023-01-10),

5. 11498892 - Fe/Cu-mediated ketone synthesis (2022-11-15),

6. 11407762 - Macrocyclic compounds and uses thereof (2022-08-09),

7. 11220513 - Chromium-mediated coupling and application to the synthesis of halichondrins (2022-01-11),

8. 11155562 - Synthesis of halichondrin analogs and uses thereof (2021-10-26),

9. 10954249 - Macrocyclic compound and uses thereof (2021-03-23),

10. 10844073 - Palladium-mediated ketolization (2020-11-24),

11. 10633392 - Chromium-mediated coupling and application to the synthesis of halichondrins (2020-04-28),

12. 10556910 - Synthesis of halichondrin analogs and uses thereof (2020-02-11),

13. 10392400 - Palladium-mediated ketolization (2019-08-27),

14. 10344038 - Chromium-mediated coupling and application to the synthesis of halichondrins (2019-07-09),

15. 9938288 - Macrocyclic compound and uses thereof (2018-04-10),

Title: The Innovations of Yoshito Kishi: Pioneering Cancer Treatments

Introduction: Yoshito Kishi, based in Cambridge, MA, is an accomplished inventor with an impressive portfolio of 18 patents. His work primarily focuses on the development of novel compounds that have significant implications in cancer treatment.

Latest Patents: Among his latest contributions to the field are two notable patents pertaining to macrocyclic compounds. The first patent describes compounds possessing tumor vascular remodeling effects and anti-cancer associated fibroblast (CAF) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and their medical applications. The second patent highlights a specific novel compound that exhibits similar tumor vascular remodeling and anti-CAF activities, reinforcing his commitment to advancing cancer therapies.

Career Highlights: Yoshito Kishi has made substantial contributions in both academia and industry. He has worked with Harvard College, where his research has influenced numerous projects in the field of medicinal chemistry. Additionally, his tenure at Eisai R&D Management Co., Ltd. has equipped him with the insights and expertise necessary to innovate within the pharmaceutical landscape.

Collaborations: Throughout his career, Kishi has collaborated with talented individuals such as Kazunobu Kira and Ken Ito. These partnerships highlight the collaborative nature of scientific research and the importance of teamwork in achieving groundbreaking innovations.

Conclusion: Yoshito Kishi exemplifies the spirit of innovation in the fight against cancer. His extensive patent portfolio and collaborative efforts demonstrate a dedication to improving medical outcomes through the development of novel therapeutics. As cancer research continues to evolve, contributions from inventors like Kishi remain crucial for future advancements.

This text is generated by artificial intelligence and may not be accurate.